[1]
|
D. B. Clifford, S. Evans, Y. Yang, E. P. Acosta, K. Goodkin and K. Tashima, “Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV Infected Individuals,” Annals of Internal Medicine, Vol. 143, No. 10, 2005, pp. 714-721.
|
[2]
|
T. Hawkins, C. Geist, B. Young, A. Giblin, R. C. Mercier, K. Thornton, et al., “Comparison of Neuropsychiatric Side Effects in an Observational Cohort of Efavirenz- and Protease Inhibitor-Treated Patients,” HIV Clinical Trials, Vol. 6, 2005, pp. 187-196.
doi:10.1310/92VR-FP24-J8GA-B49Q
|
[3]
|
C. R. Fumaz, J. A. Munoz-Moreno, J. Moltó, E. Negredo, M. J. Ferrer, G. Sirera, et al., “Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches: Quality of Life, Psychologic Issues, and Adherence,” Journal of Acquired Immune Deficiency Syndromes, Vol. 38, No. 5, 2005, pp. 560-565.
doi:10.1097/01.qai.0000147523.41993.47
|
[4]
|
R. K. Heaton, D. B. Clifford, D. R. Franklin Jr., S. P. Woods, C. Ake, et al., “HIV-Associated Neurocognitive Disorders Persist in the Era of Potent Antiretroviral Therapy CHARTER Study,” Neurology, Vol. 75, No. 23, 2010, pp. 2087-2096.
doi:10.1212/WNL.0b013e318200d727
|
[5]
|
S. Simioni, M. Cavassini, J. M. Annoni, A. R. Abraham, I. Bourquin, V. Schiffer, A. Calmy, J. P. Chave, E. Giacobini, B. Hirschel and R. A. Du Pasquier, “Cognitive Dysfunction in HIV Patients Despite Long-Standing Suppression of Viremia,” AIDS, Vol. 24, No. 9, 2010, pp. 1243-1250.
|
[6]
|
T. D. Marcotte, T. Wolfson, T. J. Rosenthal, R. K. Heaton, R. Gonzalez, R. J. Ellis and I. Grant, “HIV Neurobehavioral Research Center Group A Multimodal Assessment of Driving Performance in HIV Infection,” Neurology, Vol. 63, No. 8, 2004, pp. 1417-1422.
doi:10.1212/01.WNL.0000141920.33580.5D
|
[7]
|
T. D. Marcotte, D. Lazzaretto, J. C. Scott, E. Roberts, S. P. Woods, S. Letendre and HNRC Group, “Visual Attention Deficits Are Associated with Driving Accidents in Cognitively-Impaired HIV-Infected Individuals,” Journal of Clinical and Experimental Neuropsychology, Vol. 28, No. 1, 2006, pp. 13-28.
doi:10.1080/13803390490918048
|
[8]
|
H. Monterde, “Real Decreto 772/97 ASDE Driver-Test N-845,” Examen Psicológico de Conductores en Espa?a con Equipos Normalizados, 2005.
|
[9]
|
D. Badenes Guia, “Discriminación de la Valoración de la Capacidad de Conducción de Vehículos en Personas con Diagnóstico de Deterioro Cognitivo Ligero y Demencia en los Exámenes de Conducción Normalizados,” MAPFRE Medicina, Vol. 8, No. 2, 2007, pp. 98-107.
|
[10]
|
C. Tornero, A. Ventura, M. Bourguet and I. Poquet, “Evaluation of Driving Ability among Residents after the Duty Shift,” Accident Analysis & Prevention, Vol. 7, 2012, pp. 182-183. doi:10.1016/j.aap.2012.01.007
|
[11]
|
M. Gisslén, W. Richard, R. W. Price and S. Nilsson III, “The Definition of HIV-Associated Neurocognitive Disorders: Are We Overestimating the Real Prevalence?” BMC Infectious Diseases, Vol. 11, 2011, pp. 356-360.
doi:10.1186/1471-2334-11-356
|
[12]
|
C. Torti, E. Foca, B. M. Cesana and F. X. Lescure, “Asymptomatic Neurocognitive Disorders Inpatients Infected by HIV: Fact or Fiction?” BMC Medicine, Vol. 9, 2011, pp. 138-142. doi:10.1186/1741-7015-9-138
|
[13]
|
M. Nelson, H. J. Stellbrink, D. Podzamczer, D. Banhegyi, B. Gazzard, A. Hill and Y. van Delft, “A Comparison of Neuropsychiatric Adverse Events during 12 Weeks of Treatment with Etravirine and Efavirenz in a Treatment-Naive, HIV-1-Infected Population,” AIDS, Vol. 25, No. 3, 2011, pp. 335-340.
doi:10.1097/QAD.0b013e3283416873
|